
ABOUT IPS
IPS-Integrated Project Services is a global provider of technical consulting, architecture, engineering, project controls, construction management, and CGMP compliance services for technically complex pharmaceutical development and manufacturing facilities worldwide.
CONTACT INFORMATION
IPS-Integrated Project Services
721 Arbor Way, Suite 100
Blue Bell, PA 19422
UNITED STATES
Phone: 610.828.4090
Contact: Sales
FEATURED ARTICLES
-
The Cardinal Group was awarded the project based on an integrated delivery approach, with IPS as the Engineer of Record. Their combined technical expertise and experience is critical to the success of this aggressive schedule-driven project.
-
IPS designed a new 4x2000L (maximum production scale) multi-product, multi-phase monoclonal antibody and vaccine production facility. The greenfield site was designed to seed, scale up, harvest, and purify cell culture and vaccine products utilizing up to 100% single-use systems. The concept included six manufacturing modules of which four were identical to allow for process flexibility of different unit operations, scales, and phases of material. The other two were designed to accommodate formulation of buffer and/or media as well as other additives.
-
Our client’s objective for the flex fill project was to install a new, independent filling suite for manufacturing specialized sterile injectable products. The new line would increase capacity with a state-of-the-art flexible filling line and associated ancillary support functions. This new capability was important as a CMO. Manufacturing continued throughout the duration of the project.
-
Read how the sources of inefficiency are reduced and so are the hazards when construction components are manufactured off-site and delivered on-time.
-
Biomanufacturers seeking the best approach to rapid implementation of flexible manufacturing capacity take into account the benefits presented by different modular construction options. Here we analyze different approaches to building manufacturing capacity and assess the economic benefits of each approach.
-
Utilizing a wide range of expertise, IPS team members interfaced with MilliporeSigma’s operational group to design new layouts and processes that would optimize the facility’s flow and throughput.
-
Disagreements about design elements, execution, risk-management solutions, and safety standards are inevitable when multiple teams are working together on a project, and this can be amplified when working with teams in countries with different cultures. There are certain principles that need to be nurtured in successful project executions. To demonstrate how to effectively overcome execution challenges in a real-world project scenario, here are ten examples from our recently completed Bavarian Nordic Fill and Finish Facility for Live Viral Vaccines.
-
There are many factors in the site selection and facility design of cell therapy facilities. We summarize our experience and findings over the last five years of consideration factors behind the vertical vs. horizontal decision.
-
While companies are racing to find a vaccine and therapies to help patients, the last thing they need is for traditional construction delivery methods to challenge or even sabotage their production goals. Following are 12 strategies and solutions for accelerating the design and construction process that can yield record breaking delivery times.
-
Laboratories are an integral part of the pharmaceutical industry. They are used at each stage of the product development. See how this solution allows you to plan projects without having to build new labs and gain the ability to plan projects better, inventory management, being nimble in responding to demand fluctuations, avoidance of under and/or over utilization of talent and reliable capital project planning that is based on actual utilization tracking.
-
IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management, and validation (EPCMV) services, announces the opening of their newest office in the San Francisco Bay Area.
-
Effective vaccine production facility planning combines technological innovation, streamlined workflows, and savvy budget management to ensure project speedbumps don’t become roadblocks.
-
Both newly designed and retrofitted HVAC systems can be effective in mitigating the airborne transmission of COVID-19 and other pathogens.
-
Learn about United Therapeutics winning the Social Impact category for the 2020 ISPE Facility of the Year Award:
-
IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management, and validation (EPCMV) services, announces an employee retention plan that secures jobs for their entire global staff, nearly 1,400 employees.
-
One of the most significant moves for a growing biotech or pharmaceutical company — sometimes considered as a graduation step — is the acquisition of property to conduct clinical trials and manufacture commercial products. In the first installment of this two-part series, we will explore what considerations companies need to make before they decide what type of property to pursue.
-
Autologous (patient-derived) therapies represent unique challenges to processing. One-patient, single-batch is a radical change from the scale our industry is accustomed to. At this level the filling is more analogous to limited Phase 1 clinical trial materials or even preclinical applications. The logistics and required compliance of manufacturing these personalized therapies is drastically different and presents a combinatorial explosive problem. One aspect of this process where traditional methods fall apart is filling of these therapies.
-
Expansions and renovations to existing biological facilities, and construction of new facilities, provide a unique opportunity to rethink basic design strategies and use new technologies to build a better facility that will improve compliance. This article is the sixth in a six-part series on how single-use systems (SUS) are changing the modern biotechnology facility design and construction paradigm.
-
Cell therapies have the potential to revolutionize the biopharmaceutical world, but today’s processes, logistics, and delivery make for a challenging entry into the sector’s growth curve. As the industry evolves, we have to answer (at least) three important questions when bringing these exciting new therapies to market.
-
In 1931, Swiss doctor Paul Niehans injected a preparation of live cells from a parathyroid gland into a dying patient. The patient subsequently recovered, and Dr. Niehans had a eureka moment — that injections of living cells can have tremendous therapeutic value.